POPA ReconResearchers discovered that cancer cells use claudin proteins to bind inhibitory LILRB receptors on myeloid immune cells, reprogramming…
Researchers discovered that cancer cells use claudin proteins to bind inhibitory LILRB receptors on myeloid immune cells, reprogramming them into an immunosuppressive state that promotes tumor growth and weakens checkpoint therapy responses. Targeting this newly identified claudin–LILRB signaling axis could offer a strategy to restore anti-tumor immunity, potentially using drugs already in development. https://www.science.org/doi/10.1126/sciimmunol.adt7832
The excerpt is quoted from a public Telegram channel, which owns its text.